Medidata Honors Chiltern With Inaugural Architect Of Hope Award, Celebrating Innovation In Life Sciences

Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, is pleased to announce that Chiltern, a leading global contract research organization (CRO), is one of four recipients of the inaugural Medidata Architect of Hope Awards.

The 2016 honorees were recognized for excellence in clinical trial execution, patient impact and collaboration. The award categories—Foundation, Design and Build—align with the Architecture of Hope, the new platform branding Medidata recently launched to celebrate the vital work life sciences companies do to create medical breakthroughs, and the pivotal role technology plays in accelerating the hope they bring to patients.

Chiltern, who has been working with Medidata since 2008, was presented with the Architecture of Hope "Build" award in recognition of the CRO's successful partnership with a major biopharmaceutical company. The collaboration started with a few programmers using Medidata's integrated cloud solution for electronic data capture ( Medidata Rave ®) and has expanded to broader adoption of the Medidata Clinical Cloud ® platform, involving more than 175 members of Chiltern's staff to support the sponsor's growing portfolio.

"We are proud to be acknowledged with this esteemed recognition from Medidata," said Mark Penniston, executive vice president and general manager, clinical analytics at Chiltern. "This award speaks to the dedication and the talent that the Chiltern team brings to clinical research, and we are very proud of this accomplishment."

"Medidata is thrilled to recognize Chiltern for its dedication to delivering customized solutions that are advancing clinical research programs and helping to bring needed new therapies to patients," said Medidata's chief operating officer Mike Capone. "We share Chiltern's commitment to collaboration and look forward to our continued partnership, working together to accelerate the development of new medicines and hope for patients."

The awards were presented in front of Medidata's life sciences customers and partners at the recent 2016 Medidata Symposium in Phoenix. The annual conference provides attendees with opportunities to learn and share best practices for the effective design, planning, execution, management and reporting of clinical studies using the Medidata platform.

About Chiltern

Chiltern, a global contract research organization, is a provider of clinical solutions in a variety of specialty areas and engagement models for biopharmaceutical and medical device industries. Chiltern's team of more than 4,200, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance, Strategic Regulatory and Clinical Supplies services using a collaborative approach to maximize efficiency and minimize delays. Visit to learn more about how Chiltern is Designed Around You ®.

About Medidata

Medidata is reinventing global drug development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including nearly 800 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud ® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, from study design and planning through execution, management and reporting.

Connect with Medidata

View source version on

Copyright Business Wire 2010